Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
A six-month expansion program with Yuva Biosciences will narrow four validated AI-discovered compounds toward a nominated lead and designated backup. An amendment strengthens the exclusive cardiac disease and obesity field of use.
ELAB said it expanded its AI-driven drug discovery program with Yuva Biosciences, advancing four AI-discovered compounds toward lead nomination for cardiac disease and obesity therapeutic applications.